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Abstract Treating physicians have key roles to play in
expanded access to investigational drugs, by identifying
investigational treatment options, assessing the balance
of risks and potential benefits, informing their patients,
and applying to the regulatory authorities. This study is
the first to explore physicians’ experiences and moral
views, with the aim of understanding the conditions
under which doctors decide to pursue expanded access
for their patients and the obstacles and facilitators they
encounter in the Netherlands. In this mixed-methods
study, semi-structured interviews (n = 14) and a ques-
tionnaire (n = 90) were conducted with medical special-
ists across the country and analysed thematically. Typ-
ically, our respondents pursue expanded access in “back
against the wall” situations and broadly support its
classic requirements. They indicate practical hurdles
related to reimbursement, the amount of time and effort
required for the application, and unfamiliarity with the
regulatory process. Some physicians are morally op-
posed to expanded access, with an appeal to safety risks,
lack of evidence, and “false hope.” Some of these moral
concerns and practical obstacles may be essential targets
for change, if expanded access to unapproved drugs is to
become available for wider groups of patients for whom
standard treatment options are not—or no longer—
available, on a more consistent and equal basis.
Keywords Expanded access . Compassionate use .
Physicians’ attitudes . Clinical decision-making .Mixed
methods . Ethical issues . Moral responsibilities
Introduction
Doctors may, under strict conditions, prescribe investi-
gational drugs that are not (yet) approved for marketing
to patients who run out of standard treatment options.
This is generally referred to as “expanded access.” Al-
though terminologies and regulatory routes differ
(Kimberly et al. 2017), in many countries, expanded
access is allowed through programmes either for
(large) groups of patients or for individual patients (or
small groups of patients). In the Netherlands, these
programmes are referred to as “compassionate use”
and “named-patient” programmes, respectively (table
1). The criteria for expanded access are similar in most
countries: patients qualify when they a) are suffering
from a serious and/or life-threatening disease, b) have
exhausted standard treatment options, and c) cannot
enrol in a clinical trial (e.g., because there are no clinical
trials in their geographical area or because they fail to
meet the inclusion criteria). The treating physician must
decide based on limited data whether the investigational
drug might offer a reasonable chance at medical benefit
which outweighs the risk. In addition, in a few countries,
including the United States, Spain, and Italy, approval
from an institutional review board (IRB) is required
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On May 30, 2018, President Trump signed a federal
Right-to-Try bill into law, which allows pharmaceutical
companies under specific conditions to provide patients
with unapproved drugs without having to apply for au-
thorization by the Food and Drug Administration (FDA).
In the United States of America, the use of unapproved
drugs is not common. The FDA handles around a thou-
sand expanded access investigational new drug (IND)
applications per year (Jarow et al. 2016)—which may,
however, cover multiple patients per IND—for non-
biological drugs only. Although the American Right-to-
Try campaign aims at making unapproved drugs available
to wider groups of patients with unmet medical needs, the
bills have been heavily criticized (Bateman-House and
Robertson 2018; Holbein et al. 2015). Foremost, it is not
the FDA that keeps patients in dire circumstances from
accessing unapproved drugs; over the course of ten years,
the FDA approved 99.3 per cent of the almost nine
thousand requests it received (Jarow et al. 2016). Rather,
pharmaceutical companies may be unwilling or unable to
supply drugs outside of clinical trial settings (Darrow et al.
2015; Falit and Gross 2008), often at no cost (Miller et al.
2017). Right-to-Try legislation does little to change this,
as it does not force or stimulate pharmaceutical companies
to supply investigational drugs, nor does it provide mech-
anisms, for instance, for outcome data collection, which
might render it more attractive for companies to do so.
Also, many physicians—and patients—are unfamiliar
with expanded access and may not know that it exists or
how to pursue it (Bateman-House and Robertson 2018).
Treating physicians have key roles to play in expand-
ed access, by identifying promising new drugs, informing
patients about opportunities for trying these new drugs,
and preparing the application. Confronted with chal-
lenges ranging from reimbursement and liability issues
to lack of data on the safety and efficacy of the new drug
and the uncertainty whether the pharmaceutical company
will release the drug, expanded access “can feel like
navigating uncharted waters” (Bateman-House 2016,
¶1). To doctors, expanded access may be “a complex,
labyrinthine process” (Jerome et al. 2016, 305) and
involves an extensive administrative burden: the commu-
nication and negotiation with the pharmaceutical compa-
ny, the writing of a medical case report indicating the
rationale for trying expanded access as part of the appli-
cation process to the regulatory authorities, the obtaining
of informed consent by the patient, the reporting of
adverse events and possibly outcome data (Darrow
et al. 2015). A few years ago, the FDA made changes
to facilitate its procedures for applying for access
(Gaffney 2015). However, a recent survey study suggests
that for paediatric oncologists in the United States, the—
actual or perceived—significant burden of administrative
responsibility may still constitute a barrier to the pursuit
of compassionate use (Moerdler et al. 2019).
Very little empirical research has been conducted
into physicians’ views and experiences with regard to
expanded access to investigational drugs. This mixed-
methods study is the first to explore physicians’ experi-
ences with expanded access and their reasons for pur-
suing it (or not) for their patients through a series of
individual interviews and a questionnaire among medi-
cal specialists across the Netherlands. The Netherlands
has a system of universal health coverage and mandato-
ry health insurance. Health insurers must reimburse
approved treatments and generally do not cover the
costs of expanded access. This may explain in part
why the uptake of expanded access in the Netherlands
is similarly low as in the United States; it is estimated to
be between one hundred and two hundred applications
per year (de Visser 2016). In countries such as France
and Turkey, where investigational drugs are routinely
reimbursed through the national healthcare system, they
are more frequently prescribed (Degrassat-Théas et al.
2013; Vural et al. 2012). In France, for instance, over
21,000 patients gain access to investigational drugs
through its Autorisation Temporaire d’Utilisation
(ATU) programme every year (Agence Nationale de
Sécurité du Médicament et des produits de santé
[ANSM] 2018). The results of this study will be relevant
foremost to ethical and policy discussions on expanded
access in the Netherlands but may also be of interest to
Table 1 Expanded access in the Netherlands
Compassionate use programme Named-patient programme
Initiated by the pharmaceutical company
For (large) group of patients
Usually after successful completion of phase III clinical trial
Approval by Medicines Evaluation Board
Initiated by the treating physician
For individual patient or small group of patients
Usually possible after phase I/IIa clinical trials
Approval by Health Inspectorate
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those working in countries such as the United States and
many other European countries, in which regulatory
routes for expanded access in some respects are similar.
Methods
A mixed research design was used: individual inter-
views were conducted with medical specialists across
the Netherlands to explore their views and experiences
regarding the use of unapproved investigational drugs,
followed by a questionnaire among medical specialists
to reach a broader audience and to substantiate the
results from the interviews. We received a waiver from
the research ethics review committee of Erasmus MC
(MEC-2016-275), as the research does not fall within
the scope of the Dutch Medical Research Involving
Human Subjects Research Act. All interview respon-
dents provided oral informed consent for recording and
publication. The study was conducted in accordance
with the COREQ guidelines (Tong et al. 2007). A
COREQ checklist can be found in the Appendix.
Selection of Participants
Medical specialists were approached by email with an
invitation for an individual interview. Specialists were
selected who would likely care for patients for whom
standard treatment options may not (or no longer) be
available—in the fields of neurology, psychiatry, endo-
crinology, and (sub-specializations of) oncology—
through purposive sampling to secure a wide range of
opinions. Physicians were recruited through hospital
websites—if their email addresses were publicly
available—or scholarly publications or were contacted
through the researchers’ networks or snowball sampling.
Specialists worked in various types of hospitals (i.e., rural
hospitals, teaching hospitals, and academic hospitals) in
different regions of the Netherlands. There are three types
of hospitals in the Netherlands: rural hospitals that offer
standard care for less complex health problems (“second
line” care), teaching hospitals that are larger and affiliated
with academic hospitals, which train healthcare profes-
sionals and offer both standard and specialized (“third
line”) medical care, and academic hospitals that are con-
nected to major universities and offer both standard and
highly specialist referral medical care.
After completion of the interviews, we developed a
quantitative online questionnaire to supplement the
qualitative interview data. We cast a wide net in the
attempt to reach physicians who had experience with
expanded access. IMS Health, a health market intelli-
gence agency (which has since merged into IQVIA, a
contract research organization (IQVIA 2020)) provided
us with email addresses of a large number of Dutch
medical specialists registered under selected specializa-
tions—oncology, endocrinology, gastroenterology,
haematology, internal medicine, neurology, neurosur-
gery, infectious disease medicine, and respiratory med-
icine. Personal invitations were distributed among 5724
physicians and physicians-in-training between October
2016 and January 2017 through email and/or postal
mail. One reminder was sent by email three weeks after
the initial invitation. In February 2017, one month after
the latest mailing, the questionnaire was made publicly
accessible online and brought to the attention of physi-
cians in the researchers’ networks and through Twitter.
Interviews
Interviews were conducted with the help of a semi-
structured interview guide and included the following
topics: characteristics of the patient population and their
standard treatment options; non-standard options; views
and decision-making with regard to clinical trials, off-
label use of drugs, compassionate use or named-patient
programmes; communication and shared-decision mak-
ing; moral responsibilities of the physician; and demo-
graphic characteristics. After the first two interviews,
minor adjustments were made to the order of the ques-
tions in the interview guide to improve the course of the
interview, allowing it to converge more slowly towards
the “last-ditch option” of expanded access. The individ-
ual interviews took place at the interviewees’ workplace
or home, lasted on average between forty-five and ninety
minutes, and were conducted by NA and/or EB between
December 2015 andMay 2016. An English translation of
the interview guide can be found in the Appendix.
Questionnaire
The questionnaire was developed in LimeSurvey and
included similar topics. Participants were asked to an-
swer mostly multiple-choice questions and some free-
text questions and to rate six statements about investi-
gational drugs and physicians’ responsibilities. Free-text
questions were asked if more detailed information was
needed, for example about physicians’ experiences with
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investigational drugs, or if respondents chose “other” in
response to multiple-choice questions. Completing the
questionnaire took around ten minutes. A pilot version
was tested by seven medical specialists with different
backgrounds and two qualitative research experts and
adjusted accordingly. An English translation of the
questionnaire can be found in the Appendix.
Analysis
All interviews were audiotaped and transcribed verbatim.
Coding and analysis were performed using NVivo version
11. Interviews were coded and analysed using a constant
comparative method, in which codes were assigned and
(re)grouped into categories (themes) through multiple
readings of the interviews (Glaser and Strauss 1999;
Bradley et al. 2007). A code tree with multiple levels of
codes was developed during independent analyses of the
first three interviews by NA and EB. Discrepancies were
discussed until consensus was reached. Remaining inter-
views were coded by NA. After the analysis of the twelfth
interview, theoretical saturation was reached, and the code
tree was no longer adapted. Quotes from the interviews
were translated from Dutch by EB.
The questionnaire resulted mainly in quantitative
data. Descriptive statistics were applied to analyse the
data using SPSS, IBM Statistics, version 23.0. Valid
percentages (i.e., percentages after missing data were
excluded) are presented in tables for responses to mul-
tiple choice questions. Free-text responses were catego-
rized into themes and used for illustration.
Results
Characteristics of the Interviewees
In total, fourteen interviews with medical specialists
were conducted. Interviewees were specialists in oncol-
ogy (n = 7) with sub-specializations in hematologic,
gynaecologic, gastrointestinal, and lung cancers, neurol-
ogy (n = 3), endocrinology (n = 2), and psychiatry (n =
2). Nine worked in academic hospitals, five worked in
rural or teaching hospitals. Six out of fourteen inter-
viewees were female, and the median age was 50.0
years (interquartile range 41.8–55.3). All but one phy-
sician were (sometimes) involved in clinical research,
participating in multicentre trials conducting observa-
tional studies or early-phase clinical trials. The
interviewees treated patients for whom curative or sat-
isfactory treatment options were lacking; their patients
were either without any standard treatment options al-
together or without any standard treatment options that
sufficed. Interviewees’ characteristics are reported in
Table 2.
Characteristics of the Questionnaire Respondents
The response rate for the questionnaire following our
mailing efforts was extremely low: the questionnaire
was sent to 5724 physicians and physicians-in-training,
and we received sixty-one complete responses after the
first round of email and postal mail. After we sent
reminders and made the questionnaire publicly accessi-
ble, another sixty-eight respondents completed the ques-
tionnaire. As the characteristics of the respondents in the
first and second round did not differ, the data were
grouped and analysed together. In total, 129 respondents
completed the questionnaire. Thirty-nine respondents
were excluded as they did not work in a hospital (n =
10) or did not lack standard treatment options that could
cure their patients or prolong their lives. A total of ninety
respondents matched our target population of medical
specialists in rural, teaching, or academic hospitals who
would be in a position to consider expanded access.
Respondents’ characteristics are reported in Table 2.
Themes
We identified five themes: limited knowledge of and
experience with expanded access, disparate attitudes
towards expanded access, reasons for expanded access,
reasons against expanded access (including practical
hurdles), and views on physicians’ responsibilities re-
garding expanded access.
Limited Knowledge of and Experience with Expanded
Access
Apart from the psychiatrists and the gynaecologist, most
interviewees had had some experience with compassion-
ate use. Compassionate use programmes had mostly been
run post-trial, to bridge the gap between completion of the
clinical trial and market authorization (see Table 1).When
interviewees had applied for compassionate use, they had
treated a handful of patients, at most. The familiarity with
named-patient programmes was much more limited.
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Some interviewees (n = 3) had never heard of this route to
access an investigational drug:
Well, barely. Uhm … I never understand
completely, what it is about. (neurologist)
No, I only remember that I had to sign a statement
… about the unapproved drug so that the pharmacy
could import it. It was very complicated. I had to
write down amotivation for why I did that, and that I
would accept the responsibility for the administra-
tion and the side effects of that drug. I remember that
it was one piece of paper … This was fifteen years
ago. I have not done it since. (endocrinologist)
Other interviewees did have some experience
requesting a drug through named-patient programmes.
Their total experience typically consisted of one or a few
individual requests. Physicians working in academic
hospitals mentioned specific genetic mutations in tu-
mour biology and exclusion from a clinical trial as
reasons for having pursued named-patient expanded
access for their patients in the past.
According to our interviewees, only a small percentage
of patients ask for expanded access. These patients may
have heard about investigational treatment options in the
news, on the Internet, or from patient advocacy groups.
The largest group of patients, however, is worn out by the
time they reach the end of a standard treatment trajectory
and no longer willing to try. A doctor can usually tell who
among his or her patients will continue to look for other
options. These are commonly the patients who are proac-
tive and habituated to being in charge:
You know, beforehand you can tell which ones
are the fighters, right, the ones who will never
stop. You know that, they will go down fighting,
you know it. (oncologist)
Experiences with the Named-Patient Programme:
Questionnaire Results
In our questionnaire, nineteen respondents (21.1 per
cent) reported having had experience with requesting
an investigational drug through a named-patient pro-
gramme. All but one respondent had been able to ac-
quire the drug for their patient, and all but two claimed
Table 2 Characteristics of the interviewees and respondents
Study population
interviewees N = 14
n (%)
Study population
respondents N = 90
n (%)
Female 6 (42.9) 31 (36.5)
Male 8 (57.1) 54 (60.0)
Age
< 30 years 0 (0.0) 2 (2.3)
31 – 40 years 1 (7.1) 33 (38.4)
41 – 50 years 6 (42.9) 17 (19.8)
51 – 60 years 7 (50.0) 24 (27.9)
> 60 years 0 (0.0) 10 (11.6)
Type of employment
Medical specialist in peripheral hospital 0 (0.0) 23 (25.6)
Medical specialist in leading clinical hospital 5 (35.7) 23 (25.6)
Medical specialist in academic hospital 9 (64.3) 39 (43.3)
Medical specialist in training 0 (0.0) 5 (5.6)
Specialization
Internal medicine, oncology 7 (50.0) 14 (15.6)
Internal medicine, other specializations a 2 (14.3) 33 (36.7)
General internal medicine 0 (0.0) 16 (17.8)
Neurology 3 (21.4) 18 (20.0)
Other b, c 2 (14.3) 9 (10.0)
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that patients had benefited in some way (mostly medi-
cally) from use of the investigational drug. The costs for
the investigational drug were covered by the pharma-
ceutical company (n = 6), hospital (n = 4), health insurer
(n = 7), or by the patient (n = 1). Respondents’ experi-
ences with the application process were variable: seven
respondents experienced the process as extensive and
cumbersome, but seven other respondents said it was
quick and easy. One respondent had varying experi-
ences. In free-text responses, a gastro-intestinal oncolo-
gist and an internal oncologist commented, respectively:
“[It took] paperwork … But in the end, it did happen,”
and “[It was] a lot of administrative hassle, therefore
took a long time.” Two respondents from academic
hospitals specifically mentioned that they were support-
ed by the hospital pharmacist in applying for the unap-
proved drug. Their experience of the process was posi-
tive. One respondent noted: “Good. The pharmacist at
our department arranges these things.”
Disparate Attitudes Towards Expanded Access
Not only was the level of knowledge and experience
with expanded access highly variable across inter-
viewees, so too were their views on the desirability of
expanded access. They were more willing to consider
applying for existing compassionate use programmes
run by pharmaceutical companies than to consider
requesting expanded access for individual patients on
their own initiative. There were interviewees who were
categorically opposed to expanded access, citing the
principles of evidence-based medicine. When pressed,
they explained that they made clinical decisions in ac-
cordance with clinical guidelines and would only pre-
scribe drugs that were sufficiently tested, approved for
marketing, and suggested in clinical guidelines issued
by professional organizations.
Others were sceptical that new drugs would bring
substantial benefits to patients:
I have never felt I was held back, I have not at all
had the impression that there was a pot of gold at
the rainbow’s end, and I couldn’t reach it. Not at
all. (oncologist)
On the other hand, four interviewees were adamant
proponents of expanded access—under strict
conditions—and felt it was part of the core of their care
provision for patients. They considered it their task to
seek beyond standard treatment options or clinical
guidelines when standard options had run out but be-
lieved that not all physicians would do the same.
It is doctor-dependent and context-dependent and
knowledge-dependent and however much we
would want to have it otherwise, it is true that
these out-of-standard procedures, well, that [ac-
cess to these procedures is] not levelled. No, not
all, not everyone is equal. Not everyone has equal
chances. It is what it is. (oncologist)
Disparate Attitudes Towards Expanded Access:
Questionnaire Results
In our questionnaire, fifty-three respondents (58.9 per
cent) either agreed or strongly agreed with the statement
that physicians should not prescribe investigational
drugs outside of clinical trials (Fig. 1).
Statements:
1. I believe that physicians should not prescribe inves-
tigational drugs outside of clinical trials.
2. I believe that it is the responsibility of a physician to
refer patients without curative or life-prolonging
treatment options to (highly) specialized care.
3. I believe that it is the responsibility of a physician to
identify clinical trials in which a patient without
curative or life-prolonging treatment options may
possibly be enrolled.
4. I believe that physicians should inform their patients
about the options for accessing investigational
drugs.
5. I believe that the decision to use an investigational
drug should be made by the patient him- or herself.
6. I believe that it is the responsibility of a physician to
look, at his/her own initiative, for investigational
treatments for patients without curative or life-
prolonging treatment options.
Reasons for Expanded Access
Interviewees mentioned multiple reasons why they
would prescribe investigational drugs. The most impor-
tant reason was that it might help their patient—for
example, by improving their prognosis or quality of life.
Interviewees indicated that they would need scientific
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evidence to determine the balance of potential risks and
benefits. Respondents had different standards for what
is “enough information”: some required “positive phase
3 trials” (oncologist 1), whereas others would consider
an investigational drug based on “a sound biological
rationale” (oncologist 2) or “clinical experience after
some time without head-to-head trials” (neurologist 1)
[I should be] convinced of the possible utility [of
the drug] for this patient. Maybe in the absence of
alternatives with a prognosis that does not look
very favourable ... Well, in the back-against-the-
wall situation, I should be at ease with the little
information that I’ve got on the potential side
effects. (endocrinologist)
Interviewees often spoke of “being with their backs
against the wall” as a reason to consider expanded
access: they might pursue it (only) if there were no other
options for a patient. Two interviewees, however, men-
tioned that under very exceptional circumstances, they
would prefer to prescribe an investigational drug before
standard of care, thereby diverging from one of the
classic conditions for expanded access (i.e., that there
should be no approved alternatives). If, for instance,
standard of care consisted of combination chemothera-
py, which would wear down patients and offer a poor
prognosis, then it might be better to start with the inves-
tigational drug straightaway instead of trying standard
of care first. Of course, these interviewees thought it
preferable to enrol a patient in a clinical trial, but if trials
were non-existent, they would wish to resort to applying
for a named-patient programme before trying—
ineffective and harmful—standard of care.
In general, physical fitness was an important condi-
tion for interviewees: patients would have to be in a
relatively good condition to try an investigational drug.
At the end of a standard treatment trajectory, patients
often have long medical histories behind them and are
not physically fit enough to try investigational drugs.
Sometimes you know that you’ve got four lines of
treatment, then, then you know, like, well, if I go
and try all these lines of treatment first, the patient
will become cooked-through like butter. Then he
will not be able to try the investigational treatment.
So then I [would want to] refer him sooner.
(oncologist)
Interviewees needed to feel comfortable when pre-
scribing an investigational drug. For some, this required
not only a sufficient level of evidence about the risks
and benefits but also the favourable opinion of their
peers. Interviewees would prescribe investigational
drugs much more readily when the medical profession
made positive statements about the drug or when they
felt supported by colleagues. It is considered important
to discuss expanded access with colleagues from in- or
outside the hospital, beforehand. One interviewee re-












1 2 3 4 5 6
Statements
Totally agree Agree Neutral Disagree Totally disagree No opinion
Fig. 1 To what extent do respondents agree with statements on moral responsibilities?
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… now I had the feeling, I had enough external
information and I had, well, I had enough safe-
guards. So I did not have the idea that … I was
doing something like that [expanded access] on
my own, without anyone looking in. (psychiatrist)
In the process of expanded access, the help of a
hospital-based pharmacist was considered very valu-
able. Some interviewees mentioned that it was the
hospital-based pharmacist who had actually brought
up the possibility of expanded access and guided them
through the application process.
Reasons for Expanded Access: Questionnaire Results
Questionnaire respondents were also asked whether and
under what conditions they would consider prescribing
an investigational drug and what their reasons were for
prescribing investigational drugs outside of clinical
studies. A slight majority of forty-seven respondents
(52.2 per cent) would consider prescribing investiga-
tional drugs through compassionate use or named-
patient programmes or would support referral to a for-
eign country (based on question 13 of the questionnaire,
see Appendix). Their most important reasons for pursu-
ing expanded access pertained to patients’ health: to
improve their health, to prolong their lives, or to im-
prove quality of life (Table 3). Also, confidence in the
effectiveness of the investigational drug was an impor-
tant condition and the fact that a pharmaceutical com-
pany would offer a compassionate use programme.
None of the respondents would pursue expanded access
to provide hope, to protect the physician–patient rela-
tionship, or “because the patient will pay for it him- or
herself.”
Reasons Against Expanded Access
Interviewees mentioned a wider range of reasons not to
prescribe an investigational drug. Lack of scientific
evidence was most important in physicians’ decisions
against expanded access. Interviewees who were hesi-
tant about expanded access were sceptical about the
limited data on effectiveness and safety that is common-
ly available after phase II clinical trials, commenting that
many drugs fail in later stages of drug development.
These interviewees required more certainty regarding
the drug’s potential benefit before they would consider
exposing their patients:
After all, the one receptor is not the other. And the
fact that something works in A does not mean that
it works in B. And that a phase I study has been
conducted somewhere, does not mean anything.
At that point you are close to being nowhere.
(oncologist)
Moreover, according to interviewees in various med-
ical fields, there are very few (or no) break-through life-
saving drugs in the pharmaceutical pipeline. Inter-
viewees believed that most new drugs will not make
much of a difference to patients and that the possible
medical benefit will likely be marginal. Some inter-
viewees believed that drugs that are exceptionally ben-
eficial and/or life-saving will be evaluated fast-track and
will be quickly approved for marketing through conven-
tional channels and made available to patients. Expand-
ed access would thus not be necessary for patients:
The gains of these drugs are of course limited. If
they were very spectacular, I would have known
about them. That happened once with Herceptin,
in breast cancer. This is the only example that I
Table 3 Reasons for physicians to prescribe an investigational




To improve quality of life 24 (55.9)
Gain in health 22 (51.2)
Possible prolongation of life 19 (44.2)




Request from the patient 8 (18.6)
‘With my back against the wall’ 7 (16.3)
Collection of observational data 4 (9.3)
There are none 3 (7.0)
Request from the family of the patient 1 (2.3)
To give hope 0 (0.0)
To protect the physician-patient relationship 0 (0.0)
Patients pays for the drug himself 0 (0.0)
Other (“for rare condition with clear
pathophysiological basis”)
1 (4.7)
*Reasons for prescribing investigational drugs were mentioned by
43 of 47 respondents who would consider prescribing an investi-
gational drug. Some respondents mentioned multiple
considerations.
Bioethical Inquiry
can remember: the gains were so high that every-
one thought it was unethical to wait until the
authorization process had been completed. But
even then, you could question [whether expanded
access is appropriate]. (oncologist)
By not prescribing or proposing investigational drugs,
interviewees say they are protecting their patients against
“false hope.” Every subsequent treatment option brings
new hope for a patient. When that hope is based on only
limited data, showing limited potential formedical benefit,
it is considered false. Additionally, drugs are never with-
out risks. The principle of primum non nocere entails that
patients should be protected from such risks. A respiratory
physician states that, often, patients think that
… it does not hurt to try. But that is of course not
true, that is simply not true … Of course, you
derive hope from [investigational drugs]. And as
a doctor, too, to be honest, I always hope. (respi-
ratory physician)
Patients may be exposed to false hope, burdens, and
possible risks when trying investigational drugs.
Interviewees emphasized that it would be unethical to
expose patients to such risks without learning from it.
Data collection was considered an important condition
for expanded access, also in light of the resources (e.g.,
physicians’ time and effort, the expense of the com-
pound) dedicated to a single patient. Future patient
populations should also benefit from the knowledge that
is gathered from individual cases of expanded access:
That I findmay be the most important thing: that if
we do things outside of clinical trials, that we
register accurately what we do, so that we can
learn from it. (oncologist)
Practical Hurdles
What kept interviewees from pursuing expanded access
for their patients with unmet medical needs were most
often reasons but sometimes also practical obstacles.
Interviewees mentioned lack of experience, the admin-
istrative burden, the time and effort that it takes to
request expanded access, problems with funding or
reimbursement, and lack of cooperation by other parties,
notably pharmaceutical companies or hospital manage-
ment. An oncologist states: “No, with all of those formal
boxes you need to tick and God knows with all the
bureaucratic horror. No, there are a lot of bells and
whistles attached to it.” A respiratory physician states:
The tempo and the time and energy that you have
to put into [expanded access]. That is the biggest
problem, right? Because ultimately, you prefer
spending most of your time by the patient’s bed-
side. (respiratory physician)
Funding issues are frequently mentioned as a major
obstacle. An interviewee explains:
Then it goes to the departmental budget. And you
cannot turn to the health insurer either. You can try,
but in our experience, you immediately get: zero.
They simply look at: is this an approved drug? If it is
not approved, it does not fall in the basic package,
we do not need to reimburse it. (endocrinologist)
Reasons Against Expanded Access: Questionnaire
Results
All respondents, including respondents who had never
considered expanded access, were asked about the most
important reasons not to seek expanded access. For ques-
tionnaire respondents, themost frequently selected reasons
were safety risks, “false hope,” the low chance of effec-
tiveness, the “experimental nature” of the drug, and the
fact that there is no systematic data collection (Table 4).
Moreover, some of the reasons selected were actually
practical obstacles. Respondents were unfamiliar with the
procedure (17.8 per cent), did not know it was possible
(8.9 per cent), indicated that it was a lot of work (10.0 per
cent) and that they did not have enough time to initiate an
application process (7.8 per cent) (Table 4).
The subgroup of respondents who would consider or
had first-hand experience with prescribing or referring for
an investigational drug indicated that they would expect or
had experienced obstacles mostly related to reimburse-
ment. Almost half of the respondents (46.5 per cent)
indicated that the health insurance agency would not re-
imburse the drug, while a quarter indicated that the hospi-
tal would not (Table 5). Another major hurdle for respon-
dents was the time it takes to apply for expanded access:
39.5 per cent of respondents indicated that the application
takes too much time. Other obstacles included policies at
the hospital that discouraged doctors from using unap-
proved drugs, refusals by pharmaceutical companies, and
lack of familiarity with the regulation (Table 5).
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Views on Physicians’ Responsibilities
Regarding Expanded Access
When confronted with the question: “What do you
do when standard treatment options have been
exhausted? What do you tell your patient?” inter-
viewees often considered their moral responsibili-
ties. Interviewees in rural hospitals felt that when
they run out of standard treatment options, they
must refer patients to experts in academic hospitals.
Some academic doctors were concerned that this
does not always happen and that consequently not
all patients in the Netherlands are receiving the best
available care. In academic hospitals, it was felt,
physicians should look for promising new treatment
options, preferably for randomized controlled clini-
cal trials within the country. Being informed about
investigational treatment options was considered
part of the job of an academic medical specialist.
Also, interviewees stressed that (non-standard) treat-
ment decisions are made together with the patient and
cited the ideal of shared decision-making. About half of
the interviewees felt that when the end of a standard
treatment trajectory comes into view, they must inform
patients about all available non-standard options, in-
cluding investigational drugs. During an interview, one
physician explained:
From the very beginning here [in the academic
hospital], fifteen years ago, we have been in dia-
logue with patients, and we have said: “We’ve got
something [non-standard] for you, you don’t have
to take part, what do you think?What do you think
of the risks and benefits?” That is … I find it
disconcerting that there is this hype currently go-
ing on about this [ideal of shared decision-mak-
ing]. For to me it is self-evident that this is the way
you do things. (neurologist)
According to others, it is up to the physician to decide
whether or not expanded access is worth pursuing. Inter-
viewees highlighted that although patients can always
refuse a treatment (e.g., chemotherapy) and have the right
to a second opinion, they cannot claim access to an
investigational drug:
Table 4 Reasons for physicians not to prescribe an investigation-




Safety risks 37 (41.1)
False hope 35 (38.9)
Low chance at effectiveness 31 (34.4)
Experimental nature of the drug 30 (33.3)
No systematic data collection 23 (25.6)
Drug is not recommended in clinical
guidelines
20 (22.2)
No reimbursement of the drug 20 (22.2)
There are no promising new drugs 19 (21.1)
Costs of the drug 19 (21.1)
I wait until a clinical trial opens up 18 (20.0)
Unfamiliar with the procedure 16 (17.8)
Possible legal consequences 14 (15.6)
A lot of work 9 (10.0)
I did not know it was possible 8 (8.9)
Not enough time 7 (7.8)
Health inspectorate will not approve 4 (4.4)
There are none 2 (2.2)
Other** 6 (6.7)
*Some respondents mentioned multiple considerations.
**Mostly respondents who refer patients on or feel that the situa-
tion is not applicable to them.




Insurer does not reimburse the drug 20 (46.5%)
Application takes too much time 17 (39.5%)
Unfamiliarity with the regulation 11 (25.6%)
Hospital does not reimburse the drug 10 (23.3%)
Hospital discourages the use of
investigational drugs
8 (18.6%)






No new promising drugs 5 (11.6%)
Health inspectorate does not provide
a license or too late
5 (11.6%)
Other** 5 (11.6%)
No obstacles 2 (4.7%)
*Study population are respondents who replied that they consider
prescribing investigational drugs outside of clinical trial settings.
Some respondents mentioned multiple obstacles.
**Other includes: only in clinical trials or negative views of
expanded access.
Bioethical Inquiry
They cannot demand access to an investigational
treatment. They have no right to say: you must
give me that treatment. That is not how it works.
(oncologist)
Interviewees felt that physicians should not transfer
the responsibility for clinical decision-making to the
patient and they should determine themselves whether
or not to inform the patient about remaining options. For
example, when the patient might already be too ill or
when the physician fears that the unapproved drug
cannot be obtained (e.g., because of funding issues),
they will not tell the patient about the option. These
physicians underlined that they sought to provide only
“realistic options” to their patients:
So I find it problematic to say: “I am going to try
to get this drug for you.” I would only start to say
this if I had the idea that I would succeed in getting
the drug. (endocrinologist)
Interviewees said that instead of offering investiga-
tional treatments, they considered it their responsibility
to discuss the nearing end of life with patients and to
help patients to come to terms with the prospect of
dying. At the end of life, it was felt, patients had better
accept that their lives were going to end, spend timewith
loved ones, and say goodbye properly. Grasping at
straws is not a good way to die.
Views on Physicians’ Responsibilities
Regarding Expanded Access: Questionnaire Results
Questionnaire respondents were asked to indicate the
extent to which they agreed or disagreed with six state-
ments about physicians’ responsibilities regarding ex-
panded access (Fig. 1). Sixty-five questionnaire respon-
dents (61.1 per cent) agreed or strongly agreed with the
statement that physicians have a responsibility to refer
patients who lack satisfactory standard treatment op-
tions to more specialized care (Fig. 1). The majority
(78.9 per cent) also agreed or strongly agreed that it is
the responsibility of physicians to identify clinical trials
in which patients who lack curative or life-prolonging
treatment options may possibly be enrolled (Fig. 1).
In our questionnaire, 50 per cent of respondents
either agreed or strongly agreed with the statement that
physicians should inform their patients about existing
options to use investigational drugs (fig. 1). The major-
ity (53.3 per cent) of respondents either agreed or
strongly agreed that the decision to use an investigation-
al drug should be made by the patient him- or herself
(fig. 1). While 20 per cent of respondents felt that it is
the responsibility of treating physicians to look for in-
vestigational treatment options on their own initiative,
47.8 per cent of respondents did not (Fig. 1). Finally,
only 23.3 per cent disagreed with the statement that
physicians should not prescribe investigational drugs
outside of clinical trials (Fig. 1).
Discussion
Our study is the first to explore the experiences and
moral attitudes of physicians treating patients for whom
satisfactory standard treatment options are not (or no
longer) available, regarding expanded access to unap-
proved, investigational drugs. In our sample, the level of
awareness of existing programmes for expanded access
was variable; some respondents and interviewees had
very little knowledge of expanded access. This was not
unique to physicians working in rural hospitals; we
spoke to interviewees in academic hospitals who were
not familiar with expanded access. Our respondents and
interviewees had little personal experience with
requesting expanded access for their patients; while they
do treat patients who have run out of options, they rarely
pursue expanded access. Also, our interviewees’ moral
attitudes were heterogeneous: whereas some physicians
considered it a key component of their job to look for
investigational treatment options when the end of a
standard treatment trajectory comes into view, others
had principled objections against pursuing expanded
access, citing concerns related to lack of safety and
efficacy data, false hope, and the opportunity costs
associated with patients’ continued struggles for finding
cures. The majority (almost 60 per cent) of our ques-
tionnaire respondents felt that investigational drugs
should not be prescribed outside of clinical trials, and
only 20 per cent felt that treating physicians should
actively look for expanded access opportunities. We
observed principled objections among physicians work-
ing in academic hospitals as well as in rural or teaching
hospitals.
Some interviewees choose not to inform patients
about opportunities for expanded access to facilitate a
“good death,” associating it with acceptance and absti-
nence from life-prolonging treatment. However, it may
be paternalistic to impose such an ideal, especially as
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patients may have opposing preferences. Although
sometimes, “appropriate palliative care may be a more
suitable option for some patients than access to treat-
ments that may well prove to be ineffective and/or
unsafe” (Lewis et al. 2014, 844), patients may feel that
they should have a say in such decisions (Bunnik and
Aarts 2019). While many of our interviewees support
shared decision-making, some doctors do believe that it
is their responsibility to decide whether or not to bring
up expanded access. Physicians’ decisions whether or
not to bring it up may be influenced by patients’ phys-
ical conditions but also by doctors’ estimations of pa-
tients’ personalities (not all patients are “fighters”). This
may be done with an appeal to patients’ best interests,
but it may conflict with the medical-ethical principle of
respect for patients’ autonomy. Moreover, half of our
questionnaire respondents felt that treating physicians
should inform their patients about existing options for
accessing investigational drugs, even though many of
them may not support expanded access in principle and
may not look into it—or bring it up—in practice. Thus,
there may be a tension between physicians’ acknowl-
edged responsibility to discuss all treatment options,
including non-standard treatment options, with their
patients and their (limited) willingness to enquire into
or cooperate in expanded access.
The classic criteria for expanded access (serious/life-
threatening illness; no approved alternatives; not eligi-
ble for clinical trials; potential benefits should outweigh
the harms) were broadly upheld. Interviewees often
spoke of being “with their backs against the wall” and
having “no other options” as a reason to consider ex-
panded access. Questionnaire respondents however se-
lected “to improve quality of life,” “gain in health,”
“possible prolongation of life,” “confidence in effective-
ness,” “pharmaceutical company offers compassionate
use programme,” and “request from the patient,” more
frequently than “with my back against the wall” as
reasons to pursue access to investigational drugs outside
of clinical trials. We do not know how to explain this;
possibly, the acceptability of “being with one’s back
against the wall” as a basis for clinical decision-
making varies with the respondents’ backgrounds and
professional-cultural environments. The interviewees
who reported being with their backs against the wall as
a reason to pursue expanded access, were mostly oncol-
ogists working in academic hospitals. Questionnaire
respondents had more varied backgrounds and worked
in more varied hospital types. Respondents selected
mostly positively formulated reasons focused on benef-
icence: prolongation of life or improvement of health or
quality of life.
While interviewees supported the classic criteria for
expanded access, some did mention that when standard
of care is inadequate and associated with poor progno-
sis, they would wish to use investigational options di-
rectly, thereby diverging from a classic criterion. These
were physicians who had experience with and positive
attitudes towards expanded access. Their expressed
wish, at times, to pursue expanded access in lieu of
sub-optimal, harmful, or unsatisfactory standard of care
stands in remarkable contrast to the theme mentioned by
some other interviewees, who were not willing to coop-
erate with a request for expanded access at all, and
diverge from clinical guidelines.
Interviewees had differing opinions of the weight to be
attributed to potential harms and burdens. This disagree-
ment is reflected in the literature, where some observers
argue that when patients are terminally ill, they may
justifiably assign less importance to the (unknown) safety
risks of investigational drugs (Walker et al. 2014), where-
as other authors stress that dying patients should be
equally protected against the potential direct harms asso-
ciated with the use of unproven treatments (Dresser 2015;
Raus 2016; Yang et al. 2015).
Some interviewees claimed that, in principle, they
would not depart from evidence-based medicine and thus
disapproved of expanded access. When pressed, they ex-
plained that they only prescribe drugs that are sufficiently
studied, approved for marketing, and recommended in
clinical guidelines.When asked, for instance, whether they
would use an unapproved drug after the successful com-
pletion of a phase III clinical trial, some said they would
not, and that they would wait for marketing authorization
and/or adaptation of clinical guidelines. It seems that for
clinical decision-making, these physicians do not use
evidence—as presented in the scientific literature—per
se, but rather regulatory or professional statements regard-
ing that evidence. The frequently used “evidence-based
medicine” argument may thus have been an argumentum
ad verecundiam (appeal to authority).
Our interviewees have not pursued expanded access
because of lack of knowledge and because of principled
objections. Over a quarter of our questionnaire respon-
dents select unfamiliarity with the programmes or “I did
not know it was possible” as reasons not to pursue the use
of investigational drugs. The subgroup of respondents (n
= 43) who did have knowledge of expanded access
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(because they had either considered it or had first-hand
experience with expanded access) reported various prac-
tical obstacles, including lack of reimbursement or insti-
tutional support, and problems with health inspectorate
and pharmaceutical company. These findings mirror
practical and financial hurdles expected or observed by
experts, as expressed in the literature (Bateman-House
2016; Darrow et al. 2015; Jerome et al. 2016). In addition,
we found negative moral attitudes with regard to expand-
ed access among Dutch medical specialists.
When doctors succeeded in expanded access, the
hospital-based pharmacist had often been helpful in navi-
gating those hurdles, bringing up the possibility of trying a
compassionate use or named-patient programme and fa-
cilitating the application process. In our study, it seems that
in Dutch academic or teaching hospitals in which a phar-
macist incidentally has some experience with expanded
access, physicians may be more likely to pursue it for their
patients. This raises concerns with regard to equal access
to information and opportunities for expanded access.
These concerns are exacerbated by potential differences
between patients along the lines of socioeconomic status:
patients who are more informed and health literate may be
more likely to request expanded access and prompt their
doctors to pursue such possibilities than patients who are
less privileged. In our country, where equal access to
healthcare is deemed very important, such disparities
may need to be addressed, as demand for expanded access
is likely to increase in the future. Policymakers may con-
sider education of physicians about existing opportunities
for expanded access, and funding arrangements for ap-
proved requests, as possible ways to even out the current
expanded access landscape. If reimbursement were in
place, physicians might find it easier to pursue, arrange
for, and inform their patients about expanded access.
There are other ethical issues that merit further nor-
mative scrutiny. There is ongoing discussion, for in-
stance, and lack of evidence, on whether patients benefit
from expanded access to unapproved treatments, and
consequently, whether or not policy measures should
aim at facilitating its uptake. Also, further research
might be directed at informed consent for expanded
access, the balance of benefits and harms, dealing with
uncertainty, and questions related to physicians’ respon-
sibilities (e.g., whether or not patients should be in-
formed about opportunities for expanded access) and
payers’ responsibilities (e.g. whether or not expanded
access should be reimbursed). Discussion of these issues
is beyond the scope of this paper.
Limitations
There are several limitations to this study. First, the
results may not adequately represent Dutch medical
specialists’ views and experiences, as the response rate
to our questionnaire was extremely low. It is known
from Dutch doctors that they do not respond to invita-
tions to questionnaires in large numbers. We did not
offer any incentives. Also, IMSHealth mistakenly failed
to include the Erasmus MC logo in the invitation. Pos-
sibly, physicians’ unfamiliarity with the topic further
contributed to a low response rate. This may have intro-
duced bias; our results likely reflect the views and
experiences of those who are most willing to answer
questions about expanded access and thus most inter-
ested in the topic. This applies to our sample of inter-
viewees, too. This could mean that the level of knowl-
edge of and experience with expanded access in the
general population of medical specialists in the Nether-
lands is in fact lower than our questionnaire findings
suggest. Moreover, the study population of physicians
in the interviews and questionnaire were not completely
in line with each other. The population of interviewees
were physicians who were often more experienced with
expanded access, worked in academic hospitals, and
treated patients with more complex medical conditions.
Also, further research has yet to elucidate whether the
results of this study translate to healthcare systems in
other countries. In the United States, for instance, re-
quests for named-patient access must be evaluated by an
institutional review board (IRB), which is believed to
constitute another major practical hurdle (Borysowski
et al. 2017; Fountzilas et al. 2018), while, in the Right-
to-Try context, doctors may theoretically go ahead with-
out FDA-approval. The healthcare system in the Neth-
erlands is characterized not only by its universal health
coverage but also by its strong moral commitment to
solidarity and equal access to healthcare. Also, the
country is geographically small and professionals are
well-organized and -connected, which may explain the
importance that physicians attribute to the clinical
guidelines in certain fields (e.g., oncology). Such strong
ties may render physicians less likely to deviate from
standard of care and pursue expanded access. Moreover,
some of our respondents knew of and/or had used the
named-patient programme (only) in cases when a par-
ticular drug was temporarily unavailable (e.g., due to
production problems) and an alternative had to be
imported from another country. In the Netherlands, the
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same regulatory route is used for the import of drugs that
are approved in other countries but not submitted for
approval in the Netherlands, and for the named-patient
use of investigational drugs. In the interviews, however,
we focused exclusively on use of the named-patient
programme to prescribe investigational drugs that are
not approved for marketing anywhere in the world.
However, such particularities of the Dutch system may
have affected some of our results. Thus, our ability to
draw global conclusions from this report on a sample of
Dutch physicians’ views and experiences, is limited.
Conclusion
The level of knowledge and experience with regard to
expanded access to investigational drugs is highly vari-
able among our respondents: some doctors are not aware
of expanded access at all or have no experience with
compassionate use or named-patient programmes. Dutch
physicians encounter practical barriers, including lack of
reimbursement, unwillingness or inability of the pharma-
ceutical company to supply the drugs, and the time and
effort it takes to complete applications for expanded
access. The expertise of hospital-based pharmacists may
serve as a facilitator to expanded access. Doctors may
have negative attitudes and principled objections against
expanded access, citing safety risks and false hope, and
may choose not to bring up the possibility of expanded
access to protect their patients. It is important for patients,
patient representatives, and policymakers to know that
treating physicians’ moral attitudes or practical con-
straints may deter them from informing patients with
unmet medical needs about existing opportunities for
expanded access to investigational drugs.
COREQ checklist. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods. Study of Physicians’ Views
and Experiences in The Netherlands
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